LGOAX Fees and Costs — Patient Opportunity Trust, Class A
Data updated: 2026-08-31
The net expense ratio is 1.69%: a 0.77% management fee, a 0.25% 12b-1 fee plus 0.67% other expenses. This share class carries a maximum front-end sales load of 5.75% and a deferred sales charge of up to 1.00%. In fiscal 2025 the fund paid $1.9M in broker commissions, 0.1158% of average net assets, and portfolio turnover was 27%.
LGOAX Fees and Expenses
Annual operating expenses and sales charges of LGOAX. Prospectus, as of April 30, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.77% |
| 12b-1 fee | 0.25% |
| Other expenses | 0.67% |
| Gross expense ratio | 1.69% |
| Fee waiver | — |
| Net expense ratio | 1.69% |
| Sales charges | |
|---|---|
| Max front load | 5.75% |
| Max deferred load | 1.00% |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
LGOAX Costs Over Time
On $10,000 invested in LGOAX, assuming 5% a year before costs, total costs come to $1,781 over 5 years, cutting the return by 3.11% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $672 | $575 | $575 |
| Fund expenses (net expense ratio 1.69%) | $167 | $517 | $890 |
| Trading costs (broker commissions) | $11 | $35 | $61 |
| Lost growth on money paid in costs | $29 | $118 | $256 |
| Total costs | $880 | $1,246 | $1,781 |
| Value after costs | $9,620 | $10,330 | $10,981 |
| Impact on return, per year | 8.80% | 3.91% | 3.11% |
LGOAX Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.1158%
- Total broker commissions: $1.9M
- Bought from dealers (principal trades, not a cost): $34.8M
- Portfolio turnover (prospectus): 27%
- Securities lending: none during the year
LGOAX Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| MERRILL LYNCH INC. | $1.9M | 99.91% |
| UBS FINANCIAL SERVICES INC. | $1K | 0.06% |
| CAPITAL INSTITUTIONAL SERVICES, INC. | $400 | 0.02% |
Patient Opportunity Trust Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| MVISX | Class IS | 1.33% | none |
| LMNOX | Class I | 1.39% | none |
| LGOAX | Class A | 1.69% | 5.75% |
| LMOFX | Class FI | 1.74% | none |
| LMORX | Class R | 1.94% | none |
| LMOPX | Class C | 2.44% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.